Actym Therapeutics Announces Issuance of US Patents
Actym Therapeutics has strengthened its IP portfolio with two newly issued patents covering its novel STACT™ biological platform technology and therapeutic agents utilizing the platform. BERKELEY, Calif., June 02, 2025–(BUSINESS WIRE)–Actym Therapeutics, a clinical-stage therapeutic product development and platform company, today announced the issuance of US patent Nos. 12,201,653 and 12,226,439 by the United States